Neurologic comorbidities in patients hospitalized for COVID-19 (search done on 15 April 2020)

Added June 12, 2020

Citation: Herman C, Mayer K, Sarwal A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology. 2020 Apr 24.

What is this? Some patients with COVID-19 will have existing chronic health conditions, such as neurological conditions, and information on the prevalence of such comorbidities in patients with COVID-19 would provide useful information for those providing health care for them.

In this rapid review, the authors searched for studies of adult patients diagnosed with and treated for COVID-19 that reported data on pre-existing neurologic comorbidities or neurologic events occurring during the course of their illness. They restricted their searches to articles published in English between January and April 2020, and did the search on 15 April 2020. They included information from 31 observational studies and one randomized trial.

What was found: At the time of this review, the included studies showed a variable incidence of neurological events during the course of COVID-19 illness (ranging from 6% to 36%).

At the time of this review, the included studies showed a variable prevalence of pre-existing neurologic conditions in patients with COVID-19 infection, with a pooled prevalence of 8%

At the time of this review, the included studies showed that patients with underlying neurologic conditions may be more vulnerable to severe COVID-19 infection.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.